US Department of Health and Human Services, Strategy to Combat Opioid Abuse, Misuse, and Overdose, available at <https://www.hhs.gov/opioids/sites/default/files/2018-09/opioid-fivepoint-strategy-20180917-508compliant.pdf> (last visited September 1, 2020).+(last+visited+September+1,+2020).>Google Scholar

Substance Abuse and Mental Health Administration, Treatment of Stimulant Use Didorders. PEP20-06-001 (June 2020), available at <https://store.samhsa.gov/product/Treatment-of-Stimulant-Use-Disorder/PEP20-06-01-001> (last visited October 30, 2020).+(last+visited+October+30,+2020).>Google Scholar

American Medical Association. Issue Brief: Reports of Increases in Opioid-Related Overdose and Other Concerns During COVID Pandemic, available at <https://www.amaassn.org/system/files/2020-08/issue-brief-increases-in-opioid-related-overdose.pdf> (last visited September 1, 2020); Centers for Disease Control and Prevention, Opioid Overdose, Data Analysis and Resources, available at <https://www.cdc.gov/drugoverdose/data/analysis.html> (last visited September 1, 2020); Centers for Disease Control and Prevention, Opioid Overdose, U.S. Prescribing Rate Maps, available at <https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html> (last visited August 31, 2020); Centers for Disease Control and Prevention, CDC Newsroom, New Data Show Significant Changes in Drug Overdose Death, available at <https://www.cdc.gov/media/releases/2020/p0318-data-show-changes-overdose-deaths.html> (last visited September 1, 2020).+(last+visited+September+1,+2020);+Centers+for+Disease+Control+and+Prevention,+Opioid+Overdose,+Data+Analysis+and+Resources,+available+at++(last+visited+September+1,+2020);+Centers+for+Disease+Control+and+Prevention,+Opioid+Overdose,+U.S.+Prescribing+Rate+Maps,+available+at++(last+visited+August+31,+2020);+Centers+for+Disease+Control+and+Prevention,+CDC+Newsroom,+New+Data+Show+Significant+Changes+in+Drug+Overdose+Death,+available+at++(last+visited+September+1,+2020).>Google Scholar

National Institute on Drug Abuse, The Science of Drug Use and Addiction: The Basics, available at <https://www.drugabuse.gov/publications/media-guide/science-drug-use-addiction-basics> (last visited September 10, 2020).+(last+visited+September+10,+2020).>Google Scholar

National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy, Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse, Phillips, J.K., Ford, M.A., and Bonnie, R. J., eds. (Washington DC: National Academies Press, 2017); Evans, E. A., Harrington, C., Roose, R., Lemere, S., and Buchanan, D., “Perceived Benefits and Harms of Involuntary Civil Commitment for Opioid Use Disorder,” Journal of Law, Medicine & Ethics 48, no 4 (2020): 718–734; Udwadia, F. R. and Illes, J., “An Ethicolegal Analysis of Involuntary Treatment for Opioid Use Disorders,” Journal of Law, Medicine & Ethics 48, no. 4 (2020): 735–740.Google Scholar

National Institute on Drug Abuse, Drugs, Brains, and Behavior: The Science of Addiction. 20-DA-5605 (last revised June 2020), available at <https://www.drugabuse.gov/sites/default/files/soa.pdf> (last visited October 30, 2020).+(last+visited+October+30,+2020).>Google Scholar

Volkow, N., “Addressing the Stigma that Surrounds Addiction,” available at <https://www.drugabuse.gov/about-nida/norasblog/2020/04/addressing-stigma-surrounds-addiction> (Last visited September 10, 2020).+(Last+visited+September+10,+2020).>Google Scholar

Yang, L. H., Wong, L. Y., Grivel, M. M., and Hasin, D. S., “Stigma and Substance Use Disorders: An International Phenomenon,” Current Opinions in Psychology 30, no. 5 (2017): 378–388; Phillips, L. A. and Shaw, A, “Substance Use More Stigmatized than Smoking and Obesity,” Journal of Substance Use 18, no. 4 (2013): 247–253.CrossRefGoogle Scholar

National Institute on Drug Abuse, “Words Matter – Terms to Use and Avoid When Talking About Addiction,” available at <https://www.drugabuse.gov/nidamed-medical-health-professionals/health-professions-education/words-matter-terms-to-use-avoid-when-talking-about-addiction> (last visited September 1, 2020); Kelly, J.F., Saitz, R., and Wakeman, S. “Language, Substance use Disorders, and Policy: The Need to Reach Consensus on an ‘Addiction-ary,’” Alcoholism Treatment Quarterly 34, no. 1 (2016): 116–123.Google Scholar

Wakeman, S.E. and Barnett, M. L., “Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities,” New England Journal of Medicine 379, no. 1 (2018): 1–4.Google Scholar

Id.Google Scholar

Yang, et al., supra note 8; Hadland, S. E., Park, T. W., and Bagley, S. M., “Stigma Associated with Medication Treatment for Young Adults with Opioid Use Disorder: A Case Series,” Addiction Science & Clinical Practice 13, no. 1 (2018):15; Kelly, J. F., Wakeman, S. E., and Saitz, R., “Stop Talking ‘Dirty’: Clinicians, Language, and Quality of Care for the Leading Cause of Preventable Death in the United States,” American Journal of Medicine 128, no. 1 (2015): 8–9.CrossRefGoogle Scholar

Cooper, H. et al., “When Prescribing Isn’t Enough — Pharmacy-Level Barriers to Buprenorphine Access,” New England Journal of Medicine 383, no. 8 (2020): 703–705.Google Scholar

Nadelmann, E. and LaSalle, L., “Two Steps Forward, One Step Back: Current Harm Reduction Policy and Politics in the United States,” Harm Reduction Journal 14, no. 37 (2017): 37.Google Scholar

Harm Reduction Coalition, “Principles of Harm Reduction,” available at <https://harmreduction.org/about-us/principles-of-harm-reduction/> (last visited September 1, 2020).+(last+visited+September+1,+2020).>Google Scholar

Id.Google Scholar

Penn, LDI, “Expanding Access to Naloxone: A Review of Distribution Strategies, available at <https://ldi.upenn.edu/brief/expanding-access-naloxone-review-distribution-strategies> (last visited September 1, 2020).+(last+visited+September+1,+2020).>Google Scholar

Vowles, K. E., McEntee, M. L., Julnes, P. S., Frohe, T., Ney, J. P., and van der Goes, D. N., “Rates of Opioid Misuse, Abuse, and Addiction in Chronic Pain: A Systematic Review and Data Synthesis,” Pain 156, no. 4 (2015): 569–576.Google Scholar

Hser, Y. I., Mooney, L.J., and Saxon, A. J., et al., “High Mortality Among Patients With Opioid Use Disorder in a Large Healthcare System,” Journal of Addiction Medicine 11, no. 4 (2017): 315–319, doi: 10.1097/ADM.0000000000000312; Kerensky, T. and Walley, A.Y., “Opioid Overdose Prevention and Naloxone Rescue Kits: What We Know and What We Don’t Know,” Addiction Science & Clinical Practice 12, no. 1 (2017): 4; Abouk, R., Pacula, R. L., and Powell, D., “Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose,” JAMA Internal Medicine 179, no. 6 (2019): 805–11; McClellan, C., Lambdin, B. H., Ali, M. M., Mutter, R., et al., “Opioid-Overdose Laws Asociation with Opioid Use and Overdose Mortality,” Addictive Behaviors 86 (2018): 90–95.Google Scholar

Evans, et al., supra note 5; Udwadia and Illes, supra note 5; Jain, A., Christopher, P., and Appelbaum, P., “Civil Commitment for Opioid and Other Substance Use Disorders: Does it Work?” Psychiatric Services 69, no. 4 (2018): 374–376.CrossRefGoogle Scholar

U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Expanding Access to Family-Centered Medication-Assisted Treatment Issue Brief, available at <https://aspe.hhs.gov/basic-report/expanding-access-family-centered-medication-assisted-treatment-issue-brief> (last visited September 1, 2020); Orgera, K. and Tolbert, J., “The Opioid Epidemic and Medicaid’s Role in Facilitating Fccess to Treatment,” available at <https://www.kff.org/medicaid/issue-brief/the-opioid-epidemic-and-medicaids-role-in-facilitating-access-to-treatment/> (last visited September 1, 2020).+(last+visited+September+1,+2020);+Orgera,+K.+and+Tolbert,+J.,+“The+Opioid+Epidemic+and+Medicaid’s+Role+in+Facilitating+Fccess+to+Treatment,”+available+at++(last+visited+September+1,+2020).>Google Scholar

American Society of Addiction Medicine, National Practice Guidelines for the Treatment of Opioid Use Disorder, 2020 Focused Update, available at <https://www.asam.org/docs/default-source/quality-science/npg-jam-supplement.pdf?sfvrsn=a00a52c2_2> (last visited September 1, 2020); Mohlman, M.K. et al., “Impact of Medication-Assisted Treatment for Opioid Addiction on Medicaid Expenditures and Health Services Utilization Rates in Vermont,” Journal of Substance Abuse Treatment 67 (2016): 9–14.CrossRefGoogle Scholar

Substance Abuse and Mental Health Administration, supra note 2; Gorelick, D.A., “Treatment of Cannabis Use Disorder in Adults,” UpToDate, July 2020, available at <https://www.uptodate.com/contents/treatment-of-cannabis-use-disorder-in-adults?search=treatment%20of%20cannabis%20use%20disorder&source=search_result&selectedTitle=1~69&usage_type=default&display_rank=1> (last visited October 30, 2020).+(last+visited+October+30,+2020).>Google Scholar

Sordo, L., Barrio, G., and Bravo, M. J., et al., “Mortality Risk During and After Opioid Substitution Treatment: Systematic Review and Meta-Analysis of Cohort Studies,” BMJ 357 (2017): j1550; Gunne, L. M. and Gronbladh, L., “The Swedish Methadone Maintenance Program: A Controlled Study,” Drug and Alcohol Dependency 7, no. 3 (1981): 249–256.Google Scholar

Substance Abuse and Mental Health Services Administration, Key Substance use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health, available at <https://www.samhsa.gov/data/sites/default/files/reports/rpt29393/2019NSDUHFFRPDFWHTML/2019NSDUHFFR1PDFW090120.pdf> (last visited October 30, 2020).+(last+visited+October+30,+2020).>Google Scholar

National Academies of Sciences, Engineering, and Medicine, Medications for Opioid Use Disorder Save Lives (Washington, DC: The National Academies Press, 2019): doi: 10.17226/25310.Google Scholar

21 U.S.C. § 823(g) (2020); Tenn. Code Ann. § 53-11-311 (2020).Google Scholar

21 U.S.C. § 823(g) (2020).Google Scholar

National Institute on Drug Abuse, “Understanding Drug Use and Addiction Drug Facts,” available at <https://www.drugabuse.gov/publications/drugfacts/understanding-drug-use-addiction> (last visited on September 10, 2020).+(last+visited+on+September+10,+2020).>Google Scholar

Coyne, C. J. and Hall, A. R. “Four Decades and Counting: The Continued Failure of the War on Drugs, available at <https://www.cato.org/publications/policy-analysis/four-decades-counting-continued-failure-war-drugs> (last visited September 1, 2020); Report of the Global Commission on Drug Policy, “War on Drugs” (June 2011), available at <https://www.globalcommissionondrugs.org/wp-content/themes/gcdp_v1/pdf/Global_Commission_Report_English.pdf> (last visited September 9, 2020).+(last+visited+September+1,+2020);+Report+of+the+Global+Commission+on+Drug+Policy,+“War+on+Drugs”+(June+2011),+available+at++(last+visited+September+9,+2020).>Google Scholar

National Institute on Drug Abuse, supra note 30; Report of the Global Commission on Drug Policy, supra note 31; Drug Policy Alliance, “A Brief History of the Drug War,”available at <https://www.drugpolicy.org/issues/brief-history-drug-war> (last visited September 1, 2020).+(last+visited+September+1,+2020).>Google Scholar

E. Nadelmann and L. LaSalle, supra note 14; National Judicial Opioid Task Force, “Convening, Collaborating, Connecting: Courts as Leaders in the Crisis of Addiction,” available at <https://www.ncsc.org/__data/assets/pdf_file/0018/15840/njotf_final_report_111819.pdf> (last visited September 10, 2020).+(last+visited+September+10,+2020).>Google Scholar